Drug intelligence / Profile preview

Ultra-T

Development stage: Preclinical
Lead developer: Syenex
Modality: Gene Therapies
Administration: Intravenous

Overview

Ultra-T is an enhanced lentiviral gene delivery vector component developed by Syenex, Inc. to optimize the manufacturing of ex vivo CAR-T cell therapies. It consists of a single plasmid component that incorporates engineered viral envelopes to increase the transduction efficiency of activated primary human T cells. By boosting functional particle yield per production batch by up to 10-fold compared to standard VSV-G pseudotyped lentiviral vectors (LVVs), Ultra-T aims to reduce manufacturing costs and complexity while maintaining the phenotype and efficacy of the engineered cells. The technology is designed to be easily implementable into established LVV production protocols across both research and clinical scales.

Brand names: Ultra-T

Beyond the preview

Go deeper on Ultra-T.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ultra-T.

Explore the full profile